Upadacitinib for Sjögren's syndrome
Treatments studied
Part of Immune system & allergy clinical trials.
This study tests a new pill called upadacitinib (a JAK inhibitor) for people with active Sjögren's syndrome. It may help reduce dryness, fatigue, and joint pain by calming the immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have been diagnosed with Sjögren's syndrome using the 2016 ACR/EULAR criteria and have moderate to severe symptoms (ESSDAI score of 5 or more).
- You are currently taking a stable dose of prednisone (10 mg/day or less), hydroxychloroquine, or a dry-mouth medication.
- You have not taken any JAK inhibitor (like tofacitinib or baricitinib) before.
- You are not pregnant, breastfeeding, or have another autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called CM336 for people with primary Sjögren's syndrome (an autoimmune disease affecting salivary and tear glands). The drug is designed to help reduce disease activity in patients who haven't responded well to previous treatments.
This Phase 2 study tests how to measure changes in primary Sjögren’s syndrome symptoms and body activity. It may help researchers confirm which outcomes best reflect improvement and how different patient types respond to treatment.
This study tests an investigational drug called ICP-488 for people with primary Sjögren's syndrome (the main form, not caused by other conditions). The goal is to see if the drug can help control symptoms better than a placebo. Participants must have active disease and stable treatment.
This study tests an investigational drug called ESG206, which targets a protein on immune cells, to see if it can safely reduce symptoms of primary Sjögren's syndrome. It is for people whose Sjögren's is not caused by another disease and who have active symptoms.
This trial tests a new treatment called OL-CD19-GDT for people with systemic sclerosis or Sjögren's syndrome that hasn't responded to standard therapies. It aims to see if the treatment is safe and might help control the disease.
This trial studies whether iguratimod improves symptoms in people with primary Sjögren’s syndrome, and checks how safe it is. It focuses on people with confirmed disease markers (anti-SSA/Ro-60) and ongoing dry eyes and dry mouth.
Hear when a new Primary Sjögren's Syndrome (pSS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.